(Q33155562)

English

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 July 2017

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer (English)

1 reference

Europe PubMed Central

22 July 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles F. Levenback

5

object named as

Charles Levenback

1 reference

Europe PubMed Central

22 July 2017

Pedro T. Ramirez

1

object named as

Pedro T Ramirez

1 reference

Europe PubMed Central

22 July 2017

David Gershenson

7

object named as

David M Gershenson

1 reference

Europe PubMed Central

22 July 2017

author name string

Charles N Landen

2

1 reference

Europe PubMed Central

22 July 2017

Robert L Coleman

3

1 reference

Europe PubMed Central

22 July 2017

Michael R Milam

4

1 reference

Europe PubMed Central

22 July 2017

Taren A Johnston

6

1 reference

Europe PubMed Central

22 July 2017

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

22 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

22 July 2017

108

1 reference

Europe PubMed Central

22 July 2017

1

1 reference

Europe PubMed Central

22 July 2017

68-71

1 reference

Europe PubMed Central

22 July 2017

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.08.071

1 reference

Europe PubMed Central

22 July 2017

1 reference

Europe PubMed Central

22 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33155562&oldid=2034404557"